secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001640334-25-001880
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences appoints Mark Spring as CFO effective November 1, 2025
-------------------------------------------------------------------------

- Spring replaces Gregory Gorgas as principal financial officer and treasurer; Gorgas remains CEO.
- Spring receives $250,000 base salary, 35% target bonus, and severance of 12 months base salary (18 months on change in control).
- Gorgas amended agreement: severance increased to 24 months base salary and target bonus (36 months during CIC protection period).
- Gorgas now eligible for severance on constructive termination outside CIC period; vesting provisions revised for post-Effective Date grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001880/0001640334-25-001880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001880/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-001880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer